Management of anaphylaxis due to COVID-19 vaccines in the elderly

Jean Bousquet 1 2 3Ioana Agache 4Hubert Blain 5Marek Jutel 6 7Maria Teresa Ventura 8Margitta Worm 1Stefano Del Giacco 9Athanasios Benetos 10Beatrice Maria Bilo 11 12Wienczyslawa Czarlewski 13Amir Hamzah Abdul Latiff 14Mona Al-Ahmad 15 16Elizabeth Angier 17Isabella Annesi-Maesano 18Marina Atanaskovic-Markovic 19Claus Bachert 20 21 22 23Annick Barbaud 24 25Anna Bedbrook 14Kazi S Bennoor 26Elena Camelia Berghea 27 28Carsten Bindslev-Jensen 29Sergio Bonini 30Sinthia Bosnic-Anticevich 31 32Knut Brockow 33Luisa Brussino 34Paulo Camargos 35G Walter Canonica 36 37Victoria Cardona 38 39Pedro Carreiro-Martins 40 41Ana Carriazo 42Thomas Casale 43Jean-Christoph Caubet 44Lorenzo Cecchi 45Antonio Cherubini 46George Christoff 47Derek K Chu 48Alvaro A Cruz 49Dejan Dokic 50Yehia El-Gamal 51Motohiro Ebisawa 52Bernadette Eberlein 33John Farrell 53Montserrat Fernandez-Rivas 54Wytske J Fokkens 55 56Joao A Fonseca 57 58Yadong Gao 59Gaëtan Gavazzi 60Radoslaw Gawlik 61Asli Gelincik 62Bilun Gemicioğlu 63Maia Gotua 64Olivier Guérin 65Tari Haahtela 66Karin Hoffmann-Sommergruber 67Hans Jürgen Hoffmann 68 69Maja Hofmann 1Martin Hrubisko 70Maddalena Illario 71Carla Irani 72Zhanat Ispayeva 73Juan Carlos Ivancevich 74Kaja Julge 75Igor Kaidashev 76Musa Khaitov 77Edward Knol 78Helga Kraxner 79Piotr Kuna 80Violeta Kvedariene 81 82Antti Lauerma 83Lan T T Le 84Vincent Le Moing 85Michael Levin 86Renaud Louis 87Olga Lourenco 88Vera Mahler 89Finbarr C Martin 90Andrea Matucci 91Branislava Milenkovic 92Stéphanie Miot 5Emma Montella 71Mario Morais-Almeida 93Charlotte G Mortz 29Joaquim Mullol 94 95Leyla Namazova-Baranova 96Hugo Neffen 97Kristof Nekam 98Marek Niedoszytko 99Mikaëla Odemyr 100Robyn E O'Hehir 101Yoshitaka Okamoto 102Markus Ollert 103 104Oscar Palomares 105Nikolaos G Papadopoulos 106Petr Panzner 107Giovanni Passalacqua 108Vincenzo Patella 109Mirko Petrovic 110Oliver Pfaar 111Nhân Pham-Thi 112Davor Plavec 113 114Todor A Popov 115Marysia T Recto 116Frederico S Regateiro 117 118 119Jacques Reynes 85Regina E Roller-Winsberger 120Yves Rolland 121Antonino Romano 122 123Carmen Rondon 124 125Menachem Rottem 126 127Philip W Rouadi 128Nathalie Salles 129Boleslaw Samolinski 130Alexandra F Santos 131 132 133 134Faradiba S Sarquis 135Joaquin Sastre 136Jos M G A Schols 137Nicola Scichilone 138Anna Sediva 139Mohamed H Shamji 140 141Aziz Sheikh 142Isabel Skypala 143Sylwia Smolinska 144 145Milena Sokolowska 146Bernardo Sousa-Pinto 57 58 147Milan Sova 148Rafael Stelmach 149Gunter Sturm 150 151Charlotte Suppli Ulrik 152Ana Maria Todo-Bom 153Sanna Toppila-Salmi 66Ioanna Tsiligianni 154 155Maria Torres 156Eva Untersmayr 67Marilyn Urrutia Pereira 157Arunas Valiulis 158 159Joana Vitte 160 161Alessandra Vultaggio 91Dana Wallace 162Jolanta Walusiak-Skorupa 163De-Yun Wang 164Susan Waserman 48Arzu Yorgancioglu 165Osman M Yusuf 166Mario Zernotti 167Mihaela Zidarn 168Tomas Chivato 169Cezmi A Akdis 170Torsten Zuberbier 1Ludger Klimek 171 172

Affiliations

02 February 2021

-

doi: 10.1111/all.14838


Abstract

Older adults, especially men and/or those with diabetes, hypertension, and/or obesity, are prone to severe COVID-19. In some countries, older adults, particularly those residing in nursing homes, have been prioritized to receive COVID-19 vaccines due to high risk of death. In very rare instances, the COVID-19 vaccines can induce anaphylaxis, and the management of anaphylaxis in older people should be considered carefully. An ARIA-EAACI-EuGMS (Allergic Rhinitis and its Impact on Asthma, European Academy of Allergy and Clinical Immunology, and European Geriatric Medicine Society) Working Group has proposed some recommendations for older adults receiving the COVID-19 vaccines. Anaphylaxis to COVID-19 vaccines is extremely rare (from 1 per 100,000 to 5 per million injections). Symptoms are similar in younger and older adults but they tend to be more severe in the older patients. Adrenaline is the mainstay treatment and should be readily available. A flowchart is proposed to manage anaphylaxis in the older patients.

Keywords: COVID-19 vaccines; adrenaline; anaphylaxis; older (adults/people).

© 2021 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Conflict of interest statement

IA reports is Associate Editor Allergy and CTA. JB reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi‐Aventis, Takeda, Teva, Uriach, other from KYomed‐Innov, personal fees from Purina. VC reports personal fees from ALK, Allergy Therapeutics, LETI, Thermo Fisher, Merck, Astrazeneca, GSK. AC reports personal fees from BMS, MSD. ME reports personal fees from DBV Technologies, Mylan. MFR reports grants from ISCII (Spanish Government), Aimmune, Diater, personal fees from Aimmune, DBV, Novartis, SPRIM, ALK, Allergy Therapeutics, Diater, GSK, Thermo Fisher. BG reports grants from Astrazeneca, Novartis, MSD, Deva, Abdi Ibrahim, GSK. TH reports personal fees from GSK, Mundipharma, OrionPharma, Sanofi. LK reports grants and personal fees from Allergopharma, LETI Pharma, MEDA/Mylan, Sanofi, personal fees from HAL Allergie, Allergy Therapeut., Cassella med, grants from ALK Abelló, Stallergenes, Quintiles ASIT biotech, Lofarma, AstraZeneca, GSK, Inmunotk, and Membership: AeDA, DGHNO, Deutsche Akademie fürAllergologie und klinischeImmunologie, HNO‐BV, GPA, EAACI. PK reports personal fees from Adamed, AstraZeneca, Berlin Chemie, Boehringer Ingelheim, Hal Allergy, Lekam, Mylan, GSK, Novartis, Polpharma, Sanofi, from Teva. VK reports non‐financial support from AstraZeneca, DIMUNA, BerlinCHemieMenarini Baltic. RL reports grants from Astra Zeneca, Chiesi, GSK, other from Astra Zeneca, Novartis, GSK, Sanofi. JM reports personal fees and other from SANOFI GENZYME & REGENERON, NOVARTIS, ALLAKOS, grants and personal fees from MYLAN Pharma, URIACH Group, personal fees from Mitsubishi‐Tanabe, Menarini, UCB, AstraZeneca, GSK, MSD. MO reports grants from Astra Zeneca, Chiesi, GSK, DBV Technologies, Aimmune, Novartis, Pfizer, Regeneron, Sanofi, Boehringer Ingelheim; and volunteer President of the European Federation of Allergy and Airways Diseases Patients’ Associations EFA who receives unrestricted grants from pharmaceutical companies. Second Vice President of the Swedish Asthma and Allergy Association, who receives no income from companies. Takes part in Novartis Asthma Patient Advisory Committee, GSK Global Respiratory Patient Advisory Group and have participated/presented in AstraZeneca events. Whenever there was a honorarium, this went to EFA. OP reports research grants from Inmunotek S.L., Novartis, and MINECO. fees for giving scientific lectures or participation in Advisory Boards from Allergy Therapeutics, Amgen, AstraZeneca, Diater, GlaxoSmithKline, S.A, Inmunotek S.L, Novartis, Sanofi Genzyme and Stallergenes. NP reports personal fees from Novartis, Nutricia, HAL, MENARINI/FAES FARMA, SANOFI, MYLAN/MEDA, BIOMAY, AstraZeneca, GSK, MSD, ASIT BIOTECH, Boehringer Ingelheim, grants from Gerolymatos International SA, Capricare. OP reports grants and personal fees from ALK‐Abelló, Allergopharma, Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, BencardAllergie GmbH/Allergy Therapeutics, Lofarma, ASIT Biotech Tools S.A., rom Laboratorios LETI/LETI Pharma, Anergis S.A., Glaxo Smith Kline, personal fees from Astellas Pharma Global, MEDA Pharma/MYLAN, EUFOREA, ROXALL Medizin, Novartis, Sanofi‐Aventis, and Sanofi Genzyme, Med Update Europe GmbH, streamedup! GmbH, John Wiley and Sons, AS, Paul‐Martini‐Stiftung (PMS), Mobile Chamber Experts (a GA2LEN Partner), Indoor Biotechnologies grants from Pohl‐Boskamp, Inmunotek S.L., Biomay, Circassia. DP reports grants and personal fees from GlaxoSmithKline, personal fees and non‐financial support from Boehringer Ingelheim, personal fees from Belupo, AbbVie, MSD, Chiesi, Menarini, Pliva, Revenio, non‐financial support from Philips. YR reports grants from BIOPHYTIS, NOVARTIS. BS reports personal fees from Allergopharma, Viatris, TEVA, ADAMED, patient ombudsman, Polish Allergology Society grants from AstraZeneca, National Health Programm, grant and personal fees from Polpharma, AstraZeneca. AS reports grants and personal fees from Medical Research Council, Thermo Fisher, Buhlmann, Infomed, Nutricia and Nestle, Allergy Therapeutics, Novartis and Stallergenes, grants from Food Allergy Research and Education, Asthma UK, NIAID / Immune Tolerance Network, non‐financial support from National Institute for Health Research, Thermo Fisher and Buhlmann. Dr. Serpa reports personal fees from Takeda, personal fees and other from Novartis, personal fees from Sanofi, personal fees from GSK, other from Astra Zeneca. JS reports grants and personal fees from SANOFI, personal fees from GSK, NOVARTIS, ASTRA ZENECA, MUNDIPHARMA, FAES FARMA. AS reports grants from HDRUK. MS reports grants from Swiss National Science Foundation (SNF), GlaxoSmithKline (GSK). RS reports grants from São Paulo Research Foundation, MSD, grants and personal fees from Novartis, grants, personal fees and non‐financial support from AstraZeneca, grants, personal fees and non‐financial support from Chiesi, personal fees and non‐financial support from Boehringer Ingelheim. GS reports grants and personal fees from ALK‐Abello, personal fees from Novartis, Bencard, Stallergens, HAL, Allergopharma, Mylan. AMTB reports grants and personal fees from Teva, AstraZeneca, GSK (GlaxoSmithKline), Sanofi, Mundipharma, personal fees from Bial, grants from Leti, Novartis. STS reports personal fees from AstraZeneca, ERT, Novartis, Sanofi Pharma, Roche Products, grants from GSK. MT reports grants from European Commission, SEAIC, ISCIII, personal fees from Diater laboratory, Leti laboratory, Aimmune Therapeutics. IT reports personal fees from Honoraria for educational activities, speaking engagements, advisory boards from Boehringer Ingelheim, Astra Zeneca, GSK, Novartis and grants from GSK Hellas and Elpen. CSU reports personal fees from Astra Zeneca, personal fees from Chiesi, grants and personal fees from Novartis, Boehringer Ingelheim, personal fees from ALK‐Abello, TEVA, Orion Pharma, grants Sanofi Genzyme, personal fees and non‐financial support from GSK. IV reports personal fees from Novartis, Sanofi, personal fees and non‐financial support from Thermo Fisher, non‐financial support from Beckman Coulter. DW reports other from Kaleo, Mylan, and on the AAAAI/ACAAI Joint Task Force on Practice Parameters updating the Anaphylaxis practice parameter. SW reports other from Pfizer, Kaleo, Bausch Lomb. MW reports other from Regeneron Pharmaceuticals, DBV Technologies S.A, Stallergenes GmbH, HAL Allergie GmbH, BencardAllergie GmbH, Allergopharma GmbH & Co. KG, ALK‐AbellóArzneimittel GmbH, Mylan Germany GmbH, Leo Pharma GmbH, Sanofi‐Aventis Deutschland GmbH, Aimmune Therapeutics UK Limited, Actelion Pharmaceuticals Deutschland GmbH, Novartis AG, Biotest AG, AbbVie Deutschland GmbH & Co. KG, Lilly Deutschland GmbH. TZ reports and Organizational affiliations: Committee member: WHO‐Initiative "Allergic Rhinitis and Its Impact on Asthma" (ARIA), Member of the Board: German Society for Allergy and Clinical Immunology (DGAKI), Board Chairman: European Centre for Allergy Research Foundation (ECARF). President: Global Allergy and Asthma European Network (GA2LEN), Member: Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organization (WAO).


References

https://pubmed.ncbi.nlm.nih.gov/